Comparative analysis between ethinyl estradiol & cyperoterone acetate with or without metformin therapy in the treatment of polycyctic ovarian syndrome induced hirsutism

Authors

  • Aesha Sadaf Hameed
  • Rizwan Ahmad Malik
  • Jameel Ahmad Shaheen

Keywords:

Hirsutism, polycystic ovarian syndrome (PCOS), metformin, cyproterone acetate

Abstract

Background Hirsutism is growth of terminal hair in male pattern distribution in females. The great majority of these women have polycystic ovarian syndrome (PCOS). Current evidence suggests that patients with PCOS, whether slim or obese, have elevated levels of insulin which stimulates androgen production from ovaries, leading to hirsutism. Metformin has been shown to be effective in reducing serum insulin levels and in turn its effects.Objectives To assess the effect of oral metoformin in hirsutism.Patients and method 160 patients of hirsutism were divided in two groups. Patients in group I were administered ethinyl estradiol 35μg with cyproterone acetate 2mg (Diane 35®) for 21 days and 100mg cyproterone acetate for first ten days of the menstrual cycle. While patients in group II were administered metformin 1000mg per day in addition to the above regime. Patients were followed up at 1, 3, 6 and then 9 months interval. The variables assessedincluded; degree of hirsutism, menstrual cyclicity, body mass index, luteinising hormone,follicle stimulating hormone levels and LH/FSH ratio.Results 137 patients were evaluable whereas 23 patients lost to follow up. Out of 68 patients in group I, 22/31 (70.9%) patients with severe hirsutism improved to moderate. While 16/26 (61.5%) patients with moderate hirsutism improved to mild. Among the 69 patients of group II, 24 (72.7%) with severe hirsutism and 14 (63%) with moderate hirsutism improved to moderate and mild, respectively. However, there was little statistical difference between tworegimes (p>0,05). Menstrual cyclicity improved in 41.1% of group I patients but in 79.7% of group II patients (p<0.05). Body mass index decreased in 23% of group I but in 44% of group II patients (p<0.05). Significant decrease in luteinising hormone and LH/FSH ratio with an increase in follicle stimulating hormone levels were seen.Conclusion Metformin was found to be only marginally effective in treating hirsutism, but was highly effective in regulating menstrual cycle and decreasing obesity. It may also have an effect on improving fertility.

References

Conway GS, Honour JW, Jacobs HS.

Heterogeneity of the polycystic ovary

syndrome. Clinical, endocrine and

ultrasound features in 556 patients.

Clinical Endocrinology 1989; 30: 459-

Adams J, Polson DW, Franks S.

Prevalence of polycystic ovaries in

women with anovulation and idiopathic

hirsutism. Br Med J 1986; 293:355-9.

Ehrmann DA. Polycystic ovary

syndrome. N Engl J Med 2005; 3552:

-36.

Rotterdaam ESHRE/ASRM-sponsored

PCOS consensus workshop group.

Revised 2003 consensus on diagnostic

criteria and long term health risks related to polycystic ovary syndrome.

Fertil Steril 2003; 81: 19-25.

Legro R, Strauss J. Molecular progress

in infertility: polycystic ovary

syndrome. Fertil Steril 2003; 78: 569-

Dunaif A. Insulin resistance and the

polycystic ovarian syndrome:

mechanisms and implications for the

pathogenesis. Endocrine Rev 1997; 18:

-800.

Orio Jr F, Lucidi P, Palomba S et al.

Circulating ghrelin concentrations in the

polycystic ovary syndrome. J Clin

Endocrinol Metab 2003; 88:942-45.

Sharma A, Yousaf M, Rianna B. Recent

developments in polycystic ovary

syndrome. Progress in Obstetrics and

Gynaecology 2005; 16: 227-39.

Homburg R. Polycystic ovary syndrome

in the adolescence. New insights in

pathophysiology and treatment 2005; 8:

-49.

Mekenna T. Cyproterone acetate in the

treatment of hirsutism. Clinical

Endocrinology 2005; 35: 5-10.

Lord JM, Flight IHK, Norman RJ.

Metformin in polycystic ovary

syndrome: systemic review and metaanalysis.

Br Med J 2003; 3227: 951-56.

Aurana J, Mittal S, Kumar S et al.

Metformin therapy in women with

polycystic ovary syndrome. Int J

Gynaecol Obstet 2004; 87: 237-41.

Troncoso G, Parra A. Insulin sensitizing

drugs increase the endogenous

dopaminergic tone in obese insulinresistant

women with polycystic ovary

syndrome. J Endocrinol 2005; 184:

-39.

Lord J, Wilkin T. Metformin in

polycystic ovary syndrome. Curr Opin

Obstet Gynaecol 2004; 16: 481-86.

Muth S, Norman J, Sattar N, Fleming R.

Women with polycystic ovary

syndrome often undergo protracted

treatment with metformin and are

disinclined to stop: indications for a

change in licensing arrangements. Hum

Reprod 2004; 19: 2718-20.

Downloads

Published

2017-01-03

How to Cite

1.
Hameed AS, Malik RA, Shaheen JA. Comparative analysis between ethinyl estradiol &amp; cyperoterone acetate with or without metformin therapy in the treatment of polycyctic ovarian syndrome induced hirsutism. J Pak Assoc Dermatol [Internet]. 2017Jan.3 [cited 2026Mar.14];16(2):88-92. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/854

Issue

Section

Original Articles